Mammoth Biosciences Stock
CRISPR-Based Disease Detection Platform
Sign up today and learn more about Mammoth Biosciences Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Mammoth Biosciences Stock
Mammoth Biosciences is a developer of a CRISPR platform for diagnostic, genome editing, and protein discovery applications. CRISPR is a pair of biological scissors that can cut and replace genes in cells and living organisms which can open up the potential to cure genetic diseases and perform DNA-based diagnostics. Mammoth aims to discover new types of CRISPR systems that could be used to solve specific biological problems.Â
Mammoth Biosciences was founded by Janice Chen in 2017 and is based in San Francisco, California. Notable investors include NFX, Mayfield Fund, and Decheng Capital.
Investors
Mayfield Fund
Lyft, Jawbone, Tonal, Alchemy, Grove Collaborative, Outreach, HashiCorp, MapR Technologies, Fungible, Versa Networks
Decheng Capital
aMoon Fund
Plum Alley
Verily
Funding History
| July 2018 | $18.1M |
|---|---|
| January 2020 | $7.4M |
| January 2020 | $36.8M |
| May 2020 | $748K |
| May 2020 | $44.4M |
| July 2021 | $100M |
| July 2021 | $50.0M |
Management
Chief Executive Officer
Trevor Martin
Chief Financial Officer
Elaine Sun
Press
linkedin - Apr, 5 2024
Mammoth Biosciences on LinkedIn: #sxsw2024 #sxsw #crisprbiospace - Apr, 5 2024
Sr. Scientist I/II or Principal Scientist I - CRISPR Gene Off-Targeting Specificity job with Mammoth Biosciences | 2886672biospace - Apr, 5 2024
Senior Manager/Associate Director, FP&A job with Mammoth Biosciences | 2891098prnewswire - Dec, 26 2023
CRISPR Market worth $7.1 billion | MarketsandMarketsbiopharmadive - Dec, 26 2023
A decade later, biotech's CRISPR revolution is still going strongEquityZen Recognized As:
